October 2026

Pfizer has announced that the US Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

Bristol Myers Squibb (BMS) has announced positive results from its Phase III EXCALIBER-RRMM study, demonstrating superior progression-free survival with ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

Roche has announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III deficient mismatch repair (dMMR) colon cancer.

The government has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines, aiming to reduce medicine prices by up to 70% and provide annual savings of ₹2,500 crore to cancer patients.

Ph.D. in Biotechnology / Biochemistry / Plant Science from a recognized university and 2 years experience in Research and Development in Industrial and Academic Institutions or Science and Technology Organizations and Scientific activities and services.

Having M.D./ M.S./ M.D.S. or MBBS/ BDS/ M.VSc./ M.Sc./ M.Pharma/ M.Tech or equivalent with Ph.D. in the topic related to health research. 

Masters from a recognized University in a subject related to Biomedical Sciences OR Pharm-D degree recognized by UGC / PCI.

Master’s from a recognised University in a subject related to Biomedical Sciences OR Pharm-D degree recognised by UGC/PCI . at ICMR-National Institute of Epidemiology (NIE), Chennai under Direct Recruitment

Masters Degree in Life Sciences / Public Health / B.Pharmacy / BSc Nursing or equivalent qualification from a recognized University/Institution. AIIMS, Jodhpur